amgen glp-1 obesity drug market potential 2025 Ozempic Statistics: GLP-1 Weight Loss Medication Data amgen glp-1 obesity drug market
Description
Survodutide (BI 456906) is another promising dual GLP-1R/GCGR agonist under development for the treatment of T2D, obesity, and NASH
GLP-1 receptor agonists have transformed the management of type 2 diabetes and obesity, but their mechanism of delaying gastric emptying presents important clinical considerations
However, to date, extensive RCTs have shown no correlation between specific GLP-1 RAs and increased cancer risk
Kanaya AM
Pomytkin I, Costa-Nunes JP, Kasatkin V, Veniaminova E, Demchenko A, Lyundup A, et al
